25 June 2013
George Freeman calls on the Chancellor to support small and medium-sized enterprises emerging into the UK life science industry and highlights the role of the biomedical catalyst fund in securing over 50 projects for the UK and £1 billion in venture capital funding.
George Freeman (Mid Norfolk) (Con): What recent fiscal steps he has taken to support small businesses. [161225]
The Chancellor of the Exchequer (Mr George Osborne): Three years ago, I cut the small companies tax rate; this year, I have taken a number of further steps to support small businesses, including the new £2,000 employment allowance, which will reduce small businesses’ tax bill. Up to 1.25 million businesses will benefit, with about a third of all employers taken out of paying employer national insurance contributions altogether. We have also increased the annual investment allowance tenfold this year from £25,000 to £250,000. This directly helps small and medium-sized businesses looking to invest in the future.
...
George Freeman: In the £50 billion UK life science industry, the Chancellor’s support for the patent box, the research and development tax credits and a globally competitive corporation tax rate are helping to secure global companies here, as evidenced by Johnson & Johnson’s recent announcement of a global innovation centre here in the UK. Does he also agree that we need to support insurgent small and medium-sized enterprises emerging into the sector? I would like to highlight the role of the biomedical catalyst fund in securing over 50 projects for the UK and £1 billion in venture capital funding.
Mr Osborne: My hon. Friend’s knowledge in this area is well known, and he has applied it as a Member of Parliament to promoting schemes that help the life sciences industry—and not just the big companies, although we welcome the Johnson & Johnson announcement, but the small companies, too. The biomedical catalyst fund has been very successful at supporting small businesses in this sector. Without giving too much away about tomorrow’s announcements, I can tell him that we will go on funding this scheme.
| Hansard
George Freeman (Mid Norfolk) (Con): What recent fiscal steps he has taken to support small businesses. [161225]
The Chancellor of the Exchequer (Mr George Osborne): Three years ago, I cut the small companies tax rate; this year, I have taken a number of further steps to support small businesses, including the new £2,000 employment allowance, which will reduce small businesses’ tax bill. Up to 1.25 million businesses will benefit, with about a third of all employers taken out of paying employer national insurance contributions altogether. We have also increased the annual investment allowance tenfold this year from £25,000 to £250,000. This directly helps small and medium-sized businesses looking to invest in the future.
...
George Freeman: In the £50 billion UK life science industry, the Chancellor’s support for the patent box, the research and development tax credits and a globally competitive corporation tax rate are helping to secure global companies here, as evidenced by Johnson & Johnson’s recent announcement of a global innovation centre here in the UK. Does he also agree that we need to support insurgent small and medium-sized enterprises emerging into the sector? I would like to highlight the role of the biomedical catalyst fund in securing over 50 projects for the UK and £1 billion in venture capital funding.
Mr Osborne: My hon. Friend’s knowledge in this area is well known, and he has applied it as a Member of Parliament to promoting schemes that help the life sciences industry—and not just the big companies, although we welcome the Johnson & Johnson announcement, but the small companies, too. The biomedical catalyst fund has been very successful at supporting small businesses in this sector. Without giving too much away about tomorrow’s announcements, I can tell him that we will go on funding this scheme.
| Hansard
